Here, we tested this possibility using UNE-C1, an immune activator via TLR2/6, by coupling it to a cancer antigen derived from human papilloma virus type 16 (HPV-16) via a designed peptide linker (Figure 1A). This evidence concerns the gene TLR2 and cancer.